New pharmacological therapies for hypertension

Area of Science:

• Cardiology
• Pharmacology
• Nephrology

Background:

• Hypertension (HTN) is a primary modifiable risk factor for cardiovascular diseases (CVD), with suboptimal control rates.
• Current treatment guidelines recommend lower blood pressure (BP) targets, exacerbating control challenges.
• There is a critical need for innovative therapies to achieve consistent BP control in all patient subgroups.

Purpose of the Study:

• To review novel therapeutic strategies for hypertension.
• To assess the efficacy and safety of emerging HTN treatments.
• To address the unmet clinical need for effective BP management.

Main Methods:

• Review of recent clinical trials and therapeutic developments in hypertension management.
• Analysis of novel therapies including RNA interference (RNAi) and aldosterone synthase inhibitors (ASIs).
• Evaluation of safety, tolerability, and BP reduction across patient subgroups.

Main Results:

• Limited novel HTN therapies have emerged in the past 30 years, with existing options like renal denervation and aprocitentan having significant limitations.
• RNAi therapy Zilebesiran and ASI therapies lorundrostat and baxdrostat demonstrated significant BP reduction and good safety profiles in robust trials.
• These novel agents showed consistent efficacy across diverse patient populations.

Conclusions:

• Emerging therapies, including Zilebesiran and ASI inhibitors (lorundrostat, baxdrostat), show substantial potential for meaningful BP reduction.
• These novel treatments may improve cardiovascular and renal outcomes in hypertensive patients.
• ASI therapies are nearing regulatory approval, with future challenges in reimbursement and implementation.